Management and Characteristics of Embolism and Thrombosis After COVID-19 Vaccination: Scoping Review

Abstract

Lalipat Phianhasin,1,* Suebsarn Ruksakulpiwat,1 Suratsawadee Kruahong,1 Premgamon Kuntajak,1 Glenda B Kelman,2 Chitchanok Benjasirisan1,* 1Faculty of Nursing, Mahidol University, Bangkok, Thailand; 2Department of Nursing, Russell Sage College, Troy, NY, USA*These authors contributed equally to this workCorrespondence: Chitchanok Benjasirisan, Department of Medical Nursing, Faculty of Nursing, Mahidol University, 2 Prannok Road, Siriraj, Wanglang, Bangkoknoi, Bangkok, 10700, Thailand, Tel [phone], Email [email protected]: This scoping review aims to 1) identify characteristics of participants who developed embolism and/or thrombotic event(s) after COVID-19 vaccination and 2) review the management during the new vaccine development of the unexpected event(s). This review was conducted following PRISMA for scoping review guidelines. Peer-reviewed articles were searched for studies involving participants with embolism and/or thrombotic event(s) after COVID-19 vaccination with the management described during the early phase after the approval of vaccines. The 12 studies involving 63 participants were included in this review. The majority of participants’ ages ranged from 22 to 49 years. The embolism and/or thrombotic event(s) often occur within 30 days post-vaccination. Five of the included studies reported the event after receiving viral vector vaccines and suggested a vaccine-induced immune thrombotic thrombocytopenia as a plausible mechanism. Cerebral venous sinus thrombosis was the most frequently reported post-vaccination thrombosis complication. In summary, the most frequently reported characteristics and management from this review were consistent with international guidelines. Future studies are recommended to further investigate the incidence and additional potential complications to warrant the benefit and safety after receiving COVID-19 vaccine and other newly developed vaccines.Keywords: COVID-19 vaccine, thromboembolism, cerebral venous sinus thrombosis, vaccine-induced immune thrombotic thrombocytopenia

Keywords

• covid-19 vaccine
• thromboembolism
• cerebral venous sinus thrombosis
• vaccine-induced immune thrombotic thrombocytopenia